Turing again vows to cut drug's cost as compounder starts manufacturing a version

Turing Pharmaceuticals, which came under scrutiny for jacking up the price of an HIV drug from $13.50 per pill to $750 per pill, a 5,000% jump, is still promising to lower the cost of Daraprim. The company is now saying it will reduce the price by the end of the year and lay out measures to make the drug more affordable to patients, but did not say by how much. The move comes after compounding pharmacy Imprimis ($IMMY) said last month that it would offer a compounded drug that includes Daraprim's active ingredient, pyrimethamine, in capsules for $99 for a 100-count bottle. More from FiercePharma

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.